Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Xiao-Yin Zhang"'
Autor:
Jia-Lu Feng, Wen-Juan Wang, Peng-Fei Jin, Hui Zheng, Lai-Run Jin, Xin Xia, Xiao-Yin Zhang, Zhuo-Pei Li, Jing-Xin Li, Feng-Cai Zhu
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 19, Iss 2 (2023)
This post-hoc analysis compared the receptor-binding domain (RBD)-specific and pseudovirus neutralizing antibodies against the wild-type SARS-CoV-2 strain elicited by one or two doses (56-d interval) of Ad5-nCoV vaccine regimen (NCT04341389 and NCT04
Externí odkaz:
https://doaj.org/article/b6ec16beba044ac4a123b33b7bad66b4
Publikováno v:
PLoS Genetics, Vol 5, Iss 9, p e1000645 (2009)
Organisms like Dictyostelium discoideum, often referred to as DNA damage "extremophiles", can survive exposure to extremely high doses of radiation and DNA crosslinking agents. These agents form highly toxic DNA crosslinks that cause extensive DNA da
Externí odkaz:
https://doaj.org/article/14be99851ca94e03a5567e9882faed56
Autor:
Jing-Xin Li, Shi-Po Wu, Xi-Ling Guo, Rong Tang, Bao-Ying Huang, Xiao-Qin Chen, Yin Chen, Li-Hua Hou, Jing-Xian Liu, Jin Zhong, Hong-Xing Pan, Feng-Juan Shi, Xiao-Yu Xu, Zhuo-Pei Li, Xiao-Yin Zhang, Lun-Biao Cui, Wen-Jie Tan, Wei Chen, Feng-Cai Zhu, Hai-Tao Huang, Jin-Bo Gou, Wei-Xue Si, Xue Wang, Xiao-Long Zhao, Tao Zhu
Publikováno v:
The Lancet Respiratory Medicine. 10:739-748
Due to waning immunity and protection against infection with SARS-CoV-2, a third dose of a homologous or heterologous COVID-19 vaccine has been proposed by health agencies for individuals who were previously primed with two doses of an inactivated CO
Autor:
Rong-Hao Wei, Liang Duan, Xingliang Zhang, Qing-Ren Meng, Rong-Ruo Zhan, Chu-Xuan Ma, Jing Xu, Yi Shi, Xiao-Yin Zhang
Publikováno v:
International Geology Review. 65:1524-1540
The basal Cambrian sandstone unit in the North China craton (NCC) is an example of globally widespread siliciclastic succession that resides on the Great Unconformity and deposited on a hypothesized low-lying peneplain during the Cambrian global eust
Autor:
Rong Tang, Hui Zheng, Bu-Sen Wang, Jin-Bo Gou, Xi-Ling Guo, Xiao-Qin Chen, Yin Chen, Shi-Po Wu, Jin Zhong, Hong-Xing Pan, Jia-Hong Zhu, Xiao-Yu Xu, Feng-Juan Shi, Zhuo-Pei Li, Jing-Xian Liu, Xiao-Yin Zhang, Lun-Biao Cui, Zhi-Zhou Song, Li-Hua Hou, Feng-Cai Zhu, Jing-Xin Li, Hai-Tao Huang, Xiao-Long Li, Xue Wang, Peng Wan, Tao Zhu
Publikováno v:
The Lancet Respiratory Medicine.
Autor:
Narendranath Epperla, Nicolas Martinez-Calle, Veronika Bachanova, David Peace, Seo-Hyun Kim, Maryam Sarraf Yazdy, Andreas K. Klein, Andrew M. Evens, Neil Palmisiano, Scott E. Smith, Catherine Zhu, Manali Kamdar, Adam Zayac, Izidore S. Lossos, Catherine Diefenbach, Nadia Khan, Elizabeth H Phillips, Matthew A. Lunning, Alessia Dalla Pria, Knut B. Smeland, Chan Yoon Cheah, Adam J. Olszewski, Peter Martin, Anna Santarsieri, Kirsten M Boughan, Umar Farooq, Alexey V. Danilov, Graham P. Collins, Tycel Phillips, Reem Karmali, Alina S. Gerrie, Silvia Montoto, Stephen D. Smith, Shireen Kassam, Kevin A. David, Mark Bower, Deepa Jagadeesh, Tarec Christoffer El-Galaly, Kate Cwynarski, Suchitra Sundaram, Xiao Yin Zhang, Vaishalee P. Kenkre, Fredrik Ellin, Tatyana Feldman, Lasse Hjort Jakobsen, Craig A. Portell, Seema Naik, Nishitha Reddy, Kristie A. Blum
Publikováno v:
J Clin Oncol
Olszewski, A J, Jakobsen, L H, Collins, G P, Cwynarski, K, Bachanova, V, Blum, K A, Boughan, K M, Bower, M, Dalla Pria, A, Danilov, A, David, K A, Diefenbach, C, Ellin, F, Epperla, N, Farooq, U, Feldman, T A, Gerrie, A S, Jagadeesh, D, Kamdar, M, Karmali, R, Kassam, S, Kenkre, V P, Khan, N, Kim, S-H, Klein, A K, Lossos, I S, Lunning, M A, Martin, P, Martinez-Calle, N, Montoto, S, Naik, S, Palmisiano, N, Peace, D, Phillips, E H, Phillips, T J, Portell, C A, Reddy, N, Santarsieri, A, Sarraf Yazdy, M, Smeland, K B, Smith, S E, Smith, S D, Sundaram, S, Zayac, A S, Zhang, X-Y, Zhu, C, Cheah, C Y, El-Galaly, T C, Evens, A M & The Burkitt Lymphoma International Prognostic Index consortium 2021, ' Burkitt Lymphoma International Prognostic Index ', Journal of Clinical Oncology, vol. 39, no. 10, JCO2003288, pp. 1129-1138 . https://doi.org/10.1200/JCO.20.03288
Olszewski, A J, Jakobsen, L H, Collins, G P, Cwynarski, K, Bachanova, V, Blum, K A, Boughan, K M, Bower, M, Dalla Pria, A, Danilov, A, David, K A, Diefenbach, C, Ellin, F, Epperla, N, Farooq, U, Feldman, T A, Gerrie, A S, Jagadeesh, D, Kamdar, M, Karmali, R, Kassam, S, Kenkre, V P, Khan, N, Kim, S-H, Klein, A K, Lossos, I S, Lunning, M A, Martin, P, Martinez-Calle, N, Montoto, S, Naik, S, Palmisiano, N, Peace, D, Phillips, E H, Phillips, T J, Portell, C A, Reddy, N, Santarsieri, A, Sarraf Yazdy, M, Smeland, K B, Smith, S E, Smith, S D, Sundaram, S, Zayac, A S, Zhang, X-Y, Zhu, C, Cheah, C Y, El-Galaly, T C, Evens, A M & The Burkitt Lymphoma International Prognostic Index consortium 2021, ' Burkitt Lymphoma International Prognostic Index ', Journal of Clinical Oncology, vol. 39, no. 10, JCO2003288, pp. 1129-1138 . https://doi.org/10.1200/JCO.20.03288
PURPOSE Burkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed and validated a novel prognostic index specific for BL to aid risk stratification, interpretation of clinical trials, and tar
Autor:
Andreas K. Klein, Deepa Jagadeesh, Tarec Christoffer El-Galaly, Umar Farooq, Catherine Zhu, Nicolas Martinex-Calle, Craig A. Portell, Xiao-Yin Zhang, Adam J. Olszewski, Manali Kamdar, Andrew M. Evens, Neil Palmisiano, Tycel Phillips, Nadia Khan, Chan Yoon Cheah, Stephen D. Smith, Catherine Diefenbach, Vaishalee P. Kenkre, Reem Karmali, Silvia Montoto, Izidore S. Lossos, Graham P. Collins, Lasse Hjort Jakobsen, Alexey V. Danilov, Adam Zayac, Alina S. Gerrie, Matthew A. Lunning, Narendranath Epperla, Parameswaran Venugopal, Knut B. Smeland, Scott E. Smith, Kirsten M Boughan, Maryam Sarraf Yazdy, Suchitra Sundaram, Peter Martin, Kevin A. David, Anna Santarsieri, Alessia Dalla Pria, Nishitha Reddy, Seema Naik, Veronika Bachanova, Kristie A. Blum, David Peace, Kate Cwynarski, Elizabeth H Phillips, Shireen Kassam, Mark Bower, Tatyana Feldman, Fredrik Ellin
Publikováno v:
Blood. 136:46-49
Background. BL is a rare, high-grade B-cell lymphoma that is often studied in trials with small sample sizes. Historical definitions of "low-risk BL" vary between studies, use arbitrary cutoffs for lactate dehydrogenase (LDH), and identify a small fa
Autor:
Jing-Xin Li, Shi-Po Wu, Xi-Ling Guo, Rong Tang, Bao-Ying Huang, Xiao-Qin Chen, Hai-Tao Huang, Yin Chen, Li-Hua Hou, Jin-Bo Gou, Jing-Xian Liu, Wei-Xue Si, Jin Zhong, Xue Wang, Hong-Xing Pan, Feng-Juan Shi, Xiao-Long Zhao, Xiao-Yu Xu, Zhuo-Pei Li, Xiao-Yin Zhang, Lun-Biao Cui, Tao Zhu, Wen-Jie Tan, Wei Chen, Feng-Cai Zhu
Publikováno v:
SSRN Electronic Journal.
Autor:
Yi Liu, Xin-ping Wang, Zi-ao Zong, Rijia Lin, Xiao-yin Zhang, Fu-shan Chen, Wan-de Ding, Li-li Zhang, Xiang-min Meng, Jingwei Hou
Publikováno v:
Journal of Membrane Science. 653:120520
Twenty-five to thirty per cent of diffuse large B-cell lymphoma (DLBCL) presents as limited stage (I-II). Prognosis is generally excellent with four to six cycles of R-CHOP alone (rituximab, cyclophosphamide, vincristine, doxorubicin, prednisolone) o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e21b41514c146e83a68fe2d3c2d638a
https://doi.org/10.1111/bjh.17359
https://doi.org/10.1111/bjh.17359